-
A leading company in automotive nylon piping advertises its shares
Time of Update: 2022-09-22
After years of development, the company has become one of the few domestic joint venture brand OEMs. One of the leading companies in the supply system of automotive The prospectus shows that the company focuses on the parts supporting field of the passenger car market, providing customers with core parts with high safety and important functions.
-
The concept and definition of safety culture
Time of Update: 2022-02-11
1. The concept and definition of safety cultureSafety culture emerges and develops along with the survival and development of human beings. However, it has only been nearly thirty years since human
-
The entry of Jiangsu pharmaceutical companies has soared by more than 200
Time of Update: 2021-12-30
A few days ago, the official website of CDE showed that Jiangsu Deyuan Pharmaceutical's Enpagliflozin tablets were accepted for listing applications submitted for imitations in 4 categories .
-
Hengrui, Hausen... Great Harvest Won 24 New Anti-tumor Class 1 Drugs
Time of Update: 2021-06-17
The first domestically-made ADC drug was born, and 24 domestically-made anti-tumor Class 1 new drugs have been approved On June 9, the State Food and Drug Administration approved the listing of Rongchang Biologic’s vedicitumumab for injection, becoming the first domestic antibody-drug conjugate (ADC) in China, suitable for those who have received at least 2 types of systemic chemotherapy HER2 overexpression in patients with locally advanced or metastatic gastric cancer (including gastroesophageal junction adenocarcinoma) .
-
I've been through seven drug company safety accidents
Time of Update: 2020-08-19
Pharmaceutical enterprises in the industry more than a dozen years, dozens of safety accidents, challenged me a lot of awareness of safety protection and safety protection strategy, this article to th
-
PD-1 resistance is expected to be solved! TIM-3 Target approved clinical, Hengrui, BMS, Roche latest progress
Time of Update: 2020-07-10
Introduction: PD-1/L1 first echelon, competition for new directions foreword: Recently, Novartis in the study of TIM-3 monoclonal antibody MBG453 obtained a clinical trial license, and this antibody
